元医生智能体/内分泌/知识库
文献速递2 型糖尿病长期管理

GLP-1受体激动剂与2型糖尿病足溃疡患者下肢截肢风险

GLP‐1 Receptor Agonist Therapy Is Associated With Lower Risk of Lower Extremity Amputation in Adults With Type 2 Diabetes and Foot Ulcer Without Coded Peripheral Arterial Disease: A Hypothesis‐Generating Real‐World Cohort Study
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-10-15

本研究为真实世界回顾性队列研究，利用TriNetX全球协作网络数据，比较2型糖尿病合并糖尿病足溃疡患者使用GLP-1受体激动剂与其他降糖治疗的下肢截肢风险。结果显示GLP-1 RA使用者5年截肢风险更低，但该关联仅见于无编码外周动脉疾病患者，需前瞻性研究证实。

要点

  • GLP-1 RA与2型糖尿病足溃疡患者5年截肢风险降低相关
  • 截肢风险降低仅见于无编码外周动脉疾病患者
  • 观察性结果为假设生成性，需前瞻性研究确认

核心结论

  • 在合并糖尿病足溃疡的2型糖尿病患者中，GLP-1 RA使用与较低的下肢截肢风险相关
  • 该关联在无编码外周动脉疾病患者中显著，在编码外周动脉疾病患者中未观察到
  • 观察性结果为假设生成性，需要前瞻性研究确认

研究设计与样本

  • 新使用者、活性对照回顾性队列研究，利用TriNetX全球协作网络数据
  • 研究纳入2型糖尿病合并糖尿病足溃疡成人患者，按22个协变量进行1:1倾向评分匹配
  • 预先设定6项敏感性分析，包括30天和180天界标分析、全因死亡、背景治疗平衡等

主要发现

  • GLP-1 RA使用与5年下肢截肢风险降低相关，HR为0.60，95% CI为0.54至0.67
  • 关联仅局限于无编码外周动脉疾病亚组，HR为0.21，95% CI为0.13至0.33
  • 编码外周动脉疾病亚组中未观察到关联，HR为0.97，95% CI为0.78至1.20
  • 全因死亡率也更低，HR为0.48，95% CI为0.45至0.50
  • 与胰岛素比较的无外周动脉疾病估计值在背景治疗平衡后为0.14，肢体严重程度调整后为0.16

关键数值与推荐

  • 主要结局为5年下肢截肢风险，GLP-1 RA对比所有非GLP-1 RA治疗的HR为0.60，95% CI为0.54至0.67
  • 无编码外周动脉疾病亚组HR为0.21，95% CI为0.13至0.33
  • 编码外周动脉疾病亚组HR为0.97，95% CI为0.78至1.20
  • 风险比之比为0.21，95% CI为0.13至0.36，p值小于0.001
  • 放宽外周动脉疾病定义后无外周动脉疾病关联减弱但未消失，HR为0.34，95% CI为0.17至0.65

临床怎么用

  • 在无编码外周动脉疾病的2型糖尿病足溃疡患者中，可考虑GLP-1 RA作为降糖治疗选择之一
  • 结果仅为观察性提示，临床决策仍需个体化评估并等待前瞻性研究验证

局限性

  • 回顾性观察性研究，存在残余混杂和编码偏倚可能
  • 外周动脉疾病依据编码识别，可能低估实际患病情况
  • 研究结果来自真实世界数据，需要前瞻性研究确认因果关系

以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。

原文

ABSTRACT Aims To compare lower extremity amputation (LEA) risk in adults with Type 2 diabetes and diabetic foot ulcer (DFU) treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) versus other glucose-lowering therapy, and to test whether coded peripheral arterial disease (PAD) modifies this association and replicates across comparator classes. Materials and Methods This new-user, active-comparator retrospective cohort study used the TriNetX Global Collaborative Network (queried 11 July 2026). Adults with Type 2 diabetes and DFU were propensity-score matched 1:1 on 22 covariates, giving 21 325 pairs for the primary comparison. Effect modification by coded PAD (ICD-10 I70.2) was examined in independently matched subgroups. Six sensitivity analyses were pre-specified: 30- and 180-day landmarks, all-cause mortality, background-therapy balancing, limb-severity adjustment and a broadened PAD definition. Results GLP-1 RA use was associated with lower 5-year LEA risk than all non-GLP-1 RA therapy (hazard ratio [HR]: 0.60, 95% CI: 0.54–0.67). The association was confined to the no-PAD stratum (HR: 0.21, 0.13–0.33) and absent where PAD was coded (HR: 0.97, 0.78–1.20); ratio of hazard ratios 0.21 (0.13–0.36; p < 0.001). All-cause mortality was also lower (HR: 0.48, 0.45–0.50). The insulin no-PAD estimate persisted under background-therapy balancing (0.14), limb-severity adjustment (0.16) and 30- and 180-day landmarks (0.28, 0.33). Broadening the PAD definition attenuated the no-PAD association without abolishing it (HR: 0.34, 0.17–0.65). Conclusions In Type 2 diabetes with DFU, GLP-1 RA use was associated with lower LEA risk, surviving six pre-specified sensitivity analyses. These observational findings are hypothesis-generating and require prospective confirmation.

来源：Diabetes, Obesity and Metabolism，查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism：GLP‐1 Receptor Agonist Therapy Is Associated With Lower Risk of Lower Extremity Amputation in Adults With Type 2 Diabetes and Foot Ulcer Without Coded Peripheral Arterial Disease: A Hypothesis‐Generating Real‐World Cohort Study
在智能体中追问阅读原文 ↗

供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。